Medibact GuidesShop at Medibact

Stacking Module

IGF-1 LR3 Stacking Module

IGF-1 LR3 sits downstream of everything in the GH axis, which makes its stacking logic different from the secretagogues: it does not stimulate a pathway, it supplies the end product in a long-acting form. That is both why it is combined with GH-axis compounds and why doing so needs more care than the usual two-pathway argument.

IGF-1 LR3 Guide at MedibactIGF-1 LR3 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking IGF-1 LR3

  • IGF-1 LR3 is a modified IGF-1 with a substantially extended half-life. It acts at the IGF-1 receptor — downstream of GHRH and ghrelin signaling, not parallel to them.
  • Because GH-axis compounds work partly by raising endogenous IGF-1, adding IGF-1 LR3 is additive on the same endpoint rather than on a separate mechanism. That is a meaningful distinction from the GHRH-plus-secretagogue rationale.
  • It is dosed in micrograms and supplied in small vials (often 0.1-1 mg), so worked examples that assume a 5 or 10 mg vial do not apply.
  • No controlled trial has studied IGF-1 LR3 combined with anything, and its extended half-life means exposure is prolonged rather than pulsatile.

Combinations in detail

GH secretagogue pairing

IGF-1 LR3 + CJC-1295 + Ipamorelin
Why it is proposed
The stated logic is upstream stimulation plus downstream supply. Reported discussion frames it as covering the axis end to end.
What is reported in practice
Reported as separate vials on separate schedules, with the GH pair typically at night.
Cautions specific to this combination
This is the combination where the additive-versus-redundant question is genuinely unclear: the GH pair raises endogenous IGF-1, and IGF-1 LR3 adds exogenous IGF-1 on top. Prolonged elevation of a growth-signaling pathway is the least benign thing in this catalog to treat casually.

Local growth-factor pairing

IGF-1 LR3 + MGF
Why it is proposed
MGF (mechano growth factor) is an IGF-1 splice variant associated with local repair signaling; the pairing is framed as systemic plus local.
What is reported in practice
Reported sequentially rather than together — PEG-MGF first, IGF-1 LR3 separated by several hours, on the rationale that the two act at different phases.
Cautions specific to this combination
Both are IGF-1-family molecules, so this sits closer to a class collision than most pairings here. The sequencing rationale is community reasoning, not established pharmacology.

Recovery-oriented pairing

IGF-1 LR3 + BPC-157 + TB-500
Why it is proposed
Adds the local repair pairing, which acts through unrelated mechanisms.
What is reported in practice
Separate vials, separate schedules.
Cautions specific to this combination
Scale differences across three compounds — IGF-1 LR3's small vials in particular make copied unit figures unreliable.

What to avoid, and why

  • Assuming a worked example from a 5 or 10 mg vial applies — IGF-1 LR3 vials are often sub-milligram, and the arithmetic differs by an order of magnitude.
  • Treating IGF-1 LR3 as a parallel mechanism to GH secretagogues; it is downstream of them on the same endpoint.
  • Combining it with MGF without recognising both are IGF-1-family molecules.
  • Extending duration casually — the extended half-life means prolonged growth-pathway signaling, and long-term human safety data do not exist.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.